Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lidocaine + tranexamic acid is a compounded combination of two active pharmaceutical ingredients used primarily in surgical and procedural settings to manage pain and reduce bleeding. Lidocaine is a local anesthetic that works by blocking voltage-gated sodium channels on neuronal cell membranes, thereby inhibiting nerve impulse transmission and providing local anesthesia. Tranexamic acid is an antifibrinolytic agent that competitively inhibits the activation of plasminogen to plasmin, preventing fibrin degradation and stabilizing blood clots. This combination may be administered locally (e.g., subcutaneous injection or topical application) during procedures such as dermatologic surgery, ENT interventions (including post-tonsillectomy care), or plastic surgery to provide both hemostasis and analgesia. The use of this combination is typically tailored by compounding pharmacies for specific clinical needs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + tranexamic acid.